TY - JOUR
T1 - Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model
AU - Kaya, Melih Z.
AU - Gultekin, Yakup
AU - Celebier, Mustafa
AU - Soyseven, Murat
AU - Vural, Imran
AU - Oner, Levent
AU - Ayata, Cenk
AU - Pehlivan, Sibel Bozdag
AU - Harriott, Andrea M.
N1 - Publisher Copyright:
© 2026 Elsevier B.V.
PY - 2026/4/10
Y1 - 2026/4/10
N2 - Cortical spreading depression (SD) is the likely cause of migraine aura and a putative headache trigger. Migraine treatments, including triptans and calcitonin gene related peptide (CGRP) receptor antagonists, are limited by poor bioavailability. This study evaluates whether intranasally administered poly lactic co-glycolic acid (PLGA) based hybrid nanoparticles (HNPs) encapsulating rizatriptan (RZT) could provide sustained drug release, enhance brain delivery, and improve therapeutic efficacy against periorbital allodynia triggered by optogenetic SD in mice. CGRP8-37 was conjugated to the nanoparticle surface (HNP-CGRP8-37) and RZT encapsulated whitin HNPs (HNP-RZT). were intranasally administered alone or in combination and compared with intraperitoneal CGRP8-37 and RZT. Formulations were characterized for particle size, zeta potential, and polydispersity index, and assessed for in vitro drug release, cytotoxicity, and in vivo brain RZT concentrations. In the acute SD model, periorbital allodynia was evaluated 1 h after a single SD. In the repeated SD paradigm, seven SDs were induced every other day, and periorbital thresholds were assessed up to 6 days after the final SD. HNPs exhibited uniform particle size (<200 nm), positive zeta potential, and low polydispersity. RZT release from HNP-RZT was sustained in vitro. Intranasal HNP-RZT demonstrated prolonged brain RZT retention compared with intraperitoneal RZT. In the acute SD model, HNP-RZT did not reach statistical significance (p = 0.065), whereas intraperitoneal RZT significantly increased periorbital thresholds. In contrast, in the repeated SD model, HNP-RZT demonstrated delayed but persistent suppression of allodynia compared with intraperitoneal RZT. These findings support the potential of intranasal nanoparticle-based delivery to prolong central exposure of RZT and enhance therapeutic durability in chronic SD conditions.
AB - Cortical spreading depression (SD) is the likely cause of migraine aura and a putative headache trigger. Migraine treatments, including triptans and calcitonin gene related peptide (CGRP) receptor antagonists, are limited by poor bioavailability. This study evaluates whether intranasally administered poly lactic co-glycolic acid (PLGA) based hybrid nanoparticles (HNPs) encapsulating rizatriptan (RZT) could provide sustained drug release, enhance brain delivery, and improve therapeutic efficacy against periorbital allodynia triggered by optogenetic SD in mice. CGRP8-37 was conjugated to the nanoparticle surface (HNP-CGRP8-37) and RZT encapsulated whitin HNPs (HNP-RZT). were intranasally administered alone or in combination and compared with intraperitoneal CGRP8-37 and RZT. Formulations were characterized for particle size, zeta potential, and polydispersity index, and assessed for in vitro drug release, cytotoxicity, and in vivo brain RZT concentrations. In the acute SD model, periorbital allodynia was evaluated 1 h after a single SD. In the repeated SD paradigm, seven SDs were induced every other day, and periorbital thresholds were assessed up to 6 days after the final SD. HNPs exhibited uniform particle size (<200 nm), positive zeta potential, and low polydispersity. RZT release from HNP-RZT was sustained in vitro. Intranasal HNP-RZT demonstrated prolonged brain RZT retention compared with intraperitoneal RZT. In the acute SD model, HNP-RZT did not reach statistical significance (p = 0.065), whereas intraperitoneal RZT significantly increased periorbital thresholds. In contrast, in the repeated SD model, HNP-RZT demonstrated delayed but persistent suppression of allodynia compared with intraperitoneal RZT. These findings support the potential of intranasal nanoparticle-based delivery to prolong central exposure of RZT and enhance therapeutic durability in chronic SD conditions.
KW - CGRP
KW - Hybrid nanoparticle
KW - Migraine
KW - Optogenetic cortical spreading depression
KW - Periorbital allodynia
KW - Rizatriptan
UR - https://www.scopus.com/pages/publications/105032463162
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:001716278400001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.ijpharm.2026.126743
DO - 10.1016/j.ijpharm.2026.126743
M3 - Article
C2 - 41794348
AN - SCOPUS:105032463162
SN - 0378-5173
VL - 694
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 126743
ER -